Tempest Therapeutics (FRA:3OS0) Net Change in Cash : €-9.57 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Tempest Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Tempest Therapeutics's Net Change in Cash for the three months ended in Mar. 2025 was €-8.10 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was €-9.57 Mil.

Tempest Therapeutics Net Change in Cash Historical Data

The historical data trend for Tempest Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tempest Therapeutics Net Change in Cash Chart

Tempest Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Net Change in Cash

12.80

29.21

-19.10

7.41

-8.56

Tempest Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Change in Cash	Get a 7-Day Free Trial															-6.35	-1.12	-7.80	7.45	-8.10

Tempest Therapeutics Net Change in Cash Calculation

Tempest Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-31.541	+	-0.415	+	23.398	+	0
	=	-8.56

Tempest Therapeutics's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -7.433 + 0 + -0.667 + 0

= -8.10

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tempest Therapeutics Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Tempest Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Tempest Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tempest Therapeutics Inc (FRA:3OS0) » Definitions » Net Change in Cash

Comparable Companies

NEUP PASG NRXS BCAB LSTA ENLV NNVC OSRH CLGN VOR VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX

Traded in Other Exchanges

TPST:USA

Address

2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005

Website

https://www.tempesttx.com

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Tempest Therapeutics Headlines

No Headlines